HYBRID EVENT: You can participate in person at London, UK or Virtually from your home or work.

5th Edition of Euro-Global Conference on Biotechnology and Bioengineering

September 18-20 | Hybrid Event

September 18-20, 2025 | London, UK

Clinical Cancer Genomics

Clinical Cancer Genomics

Clinical Cancer Genomics is a rapidly evolving field that utilizes advanced genetic technologies to diagnose, treat, and understand cancer at the molecular level. By analyzing the genetic makeup of tumors, clinicians can gain invaluable insights into the underlying mechanisms driving cancer progression, leading to more precise and personalized treatment strategies. Through techniques such as next-generation sequencing (NGS) and genome-wide association studies (GWAS), researchers can identify genetic alterations, mutations, and biomarkers associated with different cancer types, aiding in early detection and prognosis. Furthermore, clinical cancer genomics plays a crucial role in identifying hereditary cancer syndromes and assessing cancer risk in individuals with a family history of the disease. Genetic testing and counseling services are integral components of clinical cancer genomics, providing patients and their families with crucial information about their genetic predisposition to cancer and informing medical management decisions. Additionally, the integration of genomic data into clinical practice enables oncologists to tailor treatment plans based on the specific molecular profile of each patient's tumor, maximizing therapeutic efficacy and minimizing adverse effects. Collaborative efforts between clinicians, researchers, and geneticists continue to drive advancements in clinical cancer genomics, paving the way for more personalized and targeted approaches to cancer care. As our understanding of cancer genetics deepens and technology continues to advance, the potential for clinical cancer genomics to revolutionize cancer diagnosis, treatment, and prevention is immense, offering hope for improved outcomes and quality of life for cancer patients worldwide.

Committee Members
Speaker at Biotechnology and Bioengineering 2025 - Michele Mishto

Michele Mishto

Francis Crick Institute, United Kingdom
Speaker at Biotechnology and Bioengineering 2025 - Thomas J Webster

Thomas J Webster

Brown University, United States
Speaker at Biotechnology and Bioengineering 2025 - Murray Moo Young

Murray Moo Young

University of Waterloo, Canada
ECBB 2025 Speakers
Speaker at Biotechnology and Bioengineering 2025 - Luis Jesus Villarreal Gomez

Luis Jesus Villarreal Gomez

Universidad Autonoma de Baja California, Mexico
Speaker at Biotechnology and Bioengineering 2025 - Assad Al Ammar

Assad Al Ammar

Specialty Enzymes and Probiotics, United States
Speaker at Biotechnology and Bioengineering 2025 - Tina Moller Tagmose

Tina Moller Tagmose

Novo Nordisk A/S, Denmark
Speaker at Biotechnology and Bioengineering 2025 - Yin Ying Ho

Yin Ying Ho

Agency for Science, Technology and Research (A*STAR), Singapore
Tags

Submit your abstract Today

Watsapp
a